Treatment of Pulmonary Embolism

Risk Stratification and Initial Management

The European Society of Cardiology recommends that treatment of pulmonary embolism (PE) must be immediately stratified by hemodynamic status, as this determines whether aggressive reperfusion therapy is warranted or anticoagulation alone suffices 1
High-risk PE is characterized by shock or persistent hypotension, and requires immediate reperfusion therapy, according to the European Heart Journal 2, 1
Intermediate-risk PE is hemodynamically stable but with evidence of right ventricular dysfunction and/or myocardial injury, and may require selective use of thrombolysis, as recommended by the European Heart Journal 2, 1
Low-risk PE is hemodynamically stable without right ventricular dysfunction, and can be managed with anticoagulation alone, according to the European Heart Journal 1

The European Heart Journal recommends that systemic thrombolysis is the first-line treatment for high-risk PE and should be administered immediately unless absolute contraindications exist 1
Unfractionated heparin (UFH) with weight-adjusted bolus and continuous infusion should be initiated without delay in high-risk PE, as recommended by the European Heart Journal 2, 1, 3
Low molecular weight heparin (LMWH) or fondaparinux is preferred over UFH for most non-high-risk patients, according to the European Heart Journal 2, 1
Direct oral anticoagulants (DOACs/NOACs) are preferred over vitamin K antagonists (VKAs) when oral anticoagulation is initiated, as recommended by the European Heart Journal 1

Surgical pulmonary embolectomy is recommended as an alternative to thrombolysis when contraindicated or failed, according to the European Heart Journal 1
Percutaneous catheter-directed treatment should be considered as an alternative to surgery when thrombolysis is contraindicated or has failed, as recommended by the European Heart Journal 1
Inferior vena cava (IVC) filters should be considered only in patients with absolute contraindications to anticoagulation or recurrent PE despite therapeutic anticoagulation, according to the European Heart Journal 1, 5

The minimum duration of anticoagulation is 3 months for all PE patients, according to Praxis Medical Insights 6
Provoked PE can be discontinued after 3 months, while unprovoked PE or recurrent VTE may require indefinite anticoagulation, as recommended by Praxis Medical Insights 6
Cancer-associated PE requires LMWH for at least 6 months, then continue as long as cancer is active, according to the European Heart Journal 2
Patients should be routinely reassessed at 3-6 months post-PE to evaluate for persistent dyspnea or functional limitation, as recommended by Praxis Medical Insights 6